Skip to main content

Advertisement

SpringerLink
Log in

Daratumumab—a novel treatment strategy in relapsed/refractory acute leukemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

The data used for this research are available from the corresponding author upon reasonable request.

References

  1. Keyhani A et al (2000) Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk Res 24:153–159

    Article  CAS  PubMed  Google Scholar 

  2. Jeyaraman P, Bhasin A, Dayal N, Pathak S, Naithani R (2020) Daratumumab in dialysis-dependent multiple myeloma. Blood Res 55(1):65–67. https://doi.org/10.5045/br.2020.55.1.65

    Article  PubMed  PubMed Central  Google Scholar 

  3. Voruz S, Blum S, de Leval L, Schoumans J, Solly F, Spertini O (2021) Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript. Biomark Res 9(1):92. https://doi.org/10.1186/s40364-021-00343-3

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ofran Y, Ringelstein-Harlev S, Slouzkey I, Zuckerman T, Yehudai-Ofir D, Henig I, Beyar-Katz O, Hayun M, Frisch A (2020) Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia. Leukemia 34(1):293–295

    Article  PubMed  Google Scholar 

  5. Stanulla M, Schewe DM, Bornhauser B, Bourquin JP, Eckert C, Eberl W, Wolf S, Wolf J, Vogiatzi F, Bergmann AK, Cario G, Beier R, Sauer M, Kratz CP, Maecker-Kolhoff B (2023) Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia. Ann Hematol 102(3):669–672. https://doi.org/10.1007/s00277-023-05083-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Borah P, Ng D, Dayal N, Pathak S, Naithani R (2023) Daratumumab-induced minimal residual disease negative remission in CD38 (dim)-positive pediatric acute myeloid leukemia. Pediatr Blood Cancer:e30347. https://doi.org/10.1002/pbc.30347

  7. Vakrmanová B, Nováková M, Říha P, Žaliová M, Froňková E, Mejstříková E, Starý J, Hrušák O, Šrámková L (2022) CD38: a target in relapsed/refractory acute lymphoblastic leukemia-limitations in treatment and diagnostics. Pediatr Blood Cancer 69(9):e29779. https://doi.org/10.1002/pbc.29779

    Article  PubMed  Google Scholar 

  8. Cerrano M, Bonifacio M, Olivi M, Curti A, Malagola M, Dargenio M, Scattolin AM, Papayannidis C, Forghieri F, Gurrieri C, Tanasi I (2022) Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study. Haematologica 107:996–999. https://doi.org/10.3324/haematol.2021.279851

    Article  PubMed  PubMed Central  Google Scholar 

  9. Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK (2016) Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128(3):384–394

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Farber M, Chen Y, Arnold L, Möllmann M, Boog-Whiteside E, Lin YA, Reinhardt HC, Dührsen U, Hanoun M (2021) Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis. Sci Rep 11(1):22062. https://doi.org/10.1038/s41598-021-01300-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Bone Marrow Transplant, Paras Health, Gurugram, 122002, India

    Pronamee Borah & Rahul Naithani

  2. Department of Lab Medicine, Max Superspecialty Hospital, Delhi, India

    Nitin Dayal

  3. Department of Transfusion Medicine, Max Superspecialty Hospital, Delhi, India

    Sangeeta Pathak

Authors
  1. Pronamee Borah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nitin Dayal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sangeeta Pathak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rahul Naithani
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study’s conception and design. Material preparation, data collection, and analysis were performed by Pronamee Borah and Rahul Naithani. Nitin Dayal was responsible for CD 38 expression in blasts in Lab. Sangeeta Pathak was responsible for hematopoietic stem cell apheresis. The first draft of the manuscript was written by Pronamee Borah. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Rahul Naithani.

Ethics declarations

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Novelty statement

Anti-CD 38 monoclonal antibody daratumumab is effective in inducing short-lived MRD-negative remissions in refractory acute leukemias.

Specific clinical relevance

Daratumumab can be used even in CD 38 dim expressor leukemia.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Borah, P., Dayal, N., Pathak, S. et al. Daratumumab—a novel treatment strategy in relapsed/refractory acute leukemia. Ann Hematol 102, 3291–3293 (2023). https://doi.org/10.1007/s00277-023-05404-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05404-1

Search

Navigation